JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

CompletedOBSERVATIONAL
Enrollment

299

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Kidney Disease, Chronic
Interventions
DRUG

JARDIANCE®

JARDIANCE®

Trial Locations (11)

10380

Inje University Ilsan Paik Hospital, Goyang

26426

Yonsei University Wonju Severance Christian Hospital, Gangwon

28644

Chungbuk National University Hospital, Cheongiu

44033

Ulsan University Hospital, Ulsan

61469

Chonnam National University Hospital, Gwangju

07441

Hallym University Sacred Heart Hospital, Anyang

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03312

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul

04401

Soonchunhyang University Hospital Seoul, Seoul

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06287073 - JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD) | Biotech Hunter | Biotech Hunter